196 related articles for article (PubMed ID: 37004887)
1. Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.
Kappelman MD; Wohl DA; Herfarth HH; Firestine AM; Adler J; Ammoury RF; Aronow JE; Bass DM; Bass JA; Benkov K; Tobi CB; Boccieri ME; Boyle BM; Brinkman WB; Cabera JM; Chun K; Colletti RB; Dodds CM; Dorsey JM; Ebach DR; Entrena E; Forrest CB; Galanko JA; Grunow JE; Gulati AS; Ivanova A; Jester TW; Kaplan JL; Kugathasan S; Kusek ME; Leibowitz IH; Linville TM; Lipstein EA; Margolis PA; Minar P; Molle-Rios Z; Moses J; Olano KK; Osaba L; Palomo PJ; Pappa H; Park KT; Pashankar DS; Pitch L; Robinson M; Samson CM; Sandberg KC; Schuchard JR; Seid M; Shelly KA; Steiner SJ; Strople JA; Sullivan JS; Tung J; Wali P; Zikry M; Weinberger M; Saeed SA; Bousvaros A
Gastroenterology; 2023 Jul; 165(1):149-161.e7. PubMed ID: 37004887
[TBL] [Abstract][Full Text] [Related]
2. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Wang Y; Tsoulis DJ; MacDonald JK; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD003459. PubMed ID: 25099640
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
7. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
Ebach DR; Jester TW; Galanko JA; Firestine AM; Ammoury R; Cabrera J; Bass J; Minar P; Olano K; Margolis P; Sandberg K; Linnville TM; Kaplan J; Pitch L; Steiner SJ; Bass D; Moses J; Adler J; Gulati AS; Wali P; Pashankar D; Ivanova A; Herfarth H; Wohl DA; Benkov KJ; Strople J; Sullivan J; Tung J; Molle-Rios Z; Saeed SA; Bousvaros A; Kappelman MD
Am J Gastroenterol; 2024 Jun; 119(6):1110-1116. PubMed ID: 38445644
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
11. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
12. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
15. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
[TBL] [Abstract][Full Text] [Related]
16. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
20. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.
Schröder O; Blumenstein I; Stein J
Eur J Gastroenterol Hepatol; 2006 Jan; 18(1):11-6. PubMed ID: 16357613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
